To elucidate (1) the challenges associated with under-recognition of bipolar disorder in obstetric settings, (2) barriers pregnant and postpartum women with bipolar disorder face when trying to access psychiatric care, and (3) how obstetric settings can identify such women and connect them with mental health services. Structured, in-depth interviews were conducted with 25 pregnant and postpartum women recruited from obstetric practices who scored ≥ 10 on the Edinburgh Postnatal Depression Scale and met DSM-IV criteria for bipolar disorder I, II, or not otherwise specified using the Mini International Neuropsychiatric Interview. Quantitative analyses included descriptive statistics. Interviews were transcribed, and resulting data were analyzed using a grounded theory approach. Most participants (n = 19, 79.17%) did not have a clinical diagnosis of bipolar disorder documented in their medical records nor had received referral for treatment during pregnancy (n = 15, 60%). Of participants receiving pharmacotherapy (n = 14, 58.33%), most were treated with an antidepressant alone (n = 10, 71.42%). Most medication was prescribed by an obstetric (n = 4, 28.57%) or primary care provider (n = 7, 50%). Qualitative interviews indicated that participants want their obstetric practices to proactively screen for, discuss and help them obtain mental health treatment. Women face challenges in securing mental health treatment appropriate to their bipolar illness. Obstetric providers provide the bulk of medical care for these women and need supports in place to (1) better recognize bipolar disorder, (2) avoid inappropriate prescribing practices for women with undiagnosed bipolar disorder, and (3) ensure women are referred to specialized treatment when needed.
Introduction
Bipolar disorder affects 3% of the general population and 23% of the perinatal (pregnant or within a year of giving birth) women who screen positive for perinatal depression (Wisner et al. 2013) . Bipolar disorder has deleterious effects on birth and child outcomes (Rusner et al. 2016) and is associated with self-injury, substance use (Geddes 1999) , disruption of mother-child bonding (Geddes 1999) , suicide, and infanticide (Lindahl et al. 2005; Spinelli 2004 ). The perinatal period is the time of highest risk for first onset or recurrence of bipolar disorder episodes (Kendell et al. 1987; Munk-Olsen et al. 2006) . Bipolar disorder is the most potent, best-established risk factor for postpartum psychosis (Jones and Craddock 2001) . Treatment access and adequacy during the perinatal time period are a critical issue, because discontinuation of pharmacotherapy increases risk for illness relapse (Jones et al. 2014) . Despite the negative impact of untreated illness and availability of effective evidence-based treatments, bipolar disorder is currently under-detected, not addressed effectively, or exacerbated through inappropriate treatment (Byatt et al. 2012 (Byatt et al. , 2017 Weinreb et al. 2014) .
Professional societies and policymakers that recommend screening for perinatal depression note that it must be accompanied by plans to ensure accurate diagnosis and appropriate treatment. This cannot be accomplished without screening, referral, and treatment of bipolar disorder (Wisner et al. 2013) . In 2015, the American College of Obstetricians and Gynecologists (2015) , the US Preventive Services Task Force (Siu et al. 2016) , and the Center for Medicaid Services (Wachino and Center for Medicaid and CHIP Services 2016) began recommending depression screening for all perinatal women. In response, obstetric practices are beginning to identify depression and provide treatment. While this is a major step forward, it poses new challenges. Because major depressive disorder is phenotypically identical to bipolar disorder when individuals are depressed, depression screening procedures that do not specifically assess for bipolar disorder do not distinguish between these illnesses. As depression screening becomes routine, resultant failure to identify and treat occult bipolar disorder in perinatal women constitutes an emerging and unmet healthcare need.
To develop approaches for identifying and treating bipolar disorder during the perinatal time period that are acceptable to patients and providers, we need to better understand their perspectives regarding what would hinder, help, and be feasible. Obstetric providers are at the front line serving pregnant and postpartum women with bipolar disorder and may be able to play a critical role in helping them access appropriate mental health care. The purpose of the study is to elucidate in a sample of perinatal women with bipolar disorder: (1) the challenges associated with under-recognition of bipolar disorder in obstetric settings, (2) what barriers they face when trying to access psychiatric care, and (3) their perspectives regarding how obstetric practices can facilitate the identification of bipolar disorder in this population and connect women with mental health care.
Methods
A descriptive exploratory study was conducted with a convenience sample of English-speaking pregnant or postpartum women aged 18-55 recruited from November 2014 to July 2016. Women were recruited during pregnancy and up to 24 months after birth from five obstetric practices associated with a large tertiary care center. The study was approved by the University of Massachusetts Institutional Review Board.
Each practice's depression screening protocol included administering the Edinburgh Postnatal Depression Scale (EPDS) (Cox et al. 1987 ) at 12-14 and/or 26-28 weeks gestational age and 6 weeks postpartum. Each practice informed patients of the study during depression screening and gave patients the opportunity to opt out of being contacted by a Research Coordinator. Patients that did not opt out and were deemed eligible based on prescreening were contacted by telephone and screened for eligibility using the three-question Composite International Diagnostic Interview Based Bipolar Disorder (CIDI) Screening (Kessler et al. 2006) . If the CIDI screen was positive, patients were invited to meet in-person and written informed consent was obtained from eligible patients. Women were eligible if they (1) had an EPDS ≥ 10 when screened by the practice, (2) were 18-55 years old, (3) were English speaking, (4) were pregnant or < 24 months postpartum, and 5) met criteria for bipolar illness as determined by the Mini International Neuropsychiatric Interview at the time of the interview (M.I.N.I.) (Sheehan et al. 1998 ). The minimum cutoff on the EPDS used to indicate possible depression ranges from 9 to 13 in relevant literature. Consistent with recommendations by Gibson et al. (2009) and many studies in the peer reviewed literature (Burton et al. 2011; Chaudron et al. 2005; Chen et al. 2011; Flynn et al. 2006; Glavin et al. 2009 Glavin et al. , 2010 Goodman and TyerViola 2010) , we used a cutoff of 10 to ensure that we captured most or all women with scores requiring further assessment. Women who completed the study received a US $15 gift card.
Participants also completed the Barriers to Access to Care Evaluation (BACE). The BACE is a 30-item self-administered tool, with demonstrated reliability, validity, and acceptability, that assesses barriers to accessing mental health care, including a Btreatment stigma^subscale (Clement et al. 2012) . BACE scores range from zero to three with higher scores indicating more barriers or stigma. The EPDS (Cox et al. 1987 ) is a validated, self-administered 10-item screening questionnaire for which the scores range from 0 to 30, with higher scores reflecting greater symptom severity (Cox et al. 1987) . The structured interview obtained demographics and factors associated with mental health treatment participation. After excluding one participant due to the medical record being unavailable, pharmacotherapy during pregnancy and within 1 year postpartum was abstracted from the medical record for 24 participants.
Twenty-minute in-depth interviews in which participants responded to study probes regarding the barriers and facilitators to mental health treatment were also conducted. Recordings were cleaned of any identifying data, transcribed, and checked for accuracy. Transcripts were uploaded into Dedoose (2012) , a web-based software program that facilitates mixed methods data management for further coding, elaboration, and specification of concepts and relationships. Interview content was organized theoretically, using a modified grounded theory approach with a phenomenological emphasis (Morgan 1988). Using methods described by Miles and Huberman (1994) , categorizing began with an initial set of preliminary codes for themes suggested from the literature, research aims, and previous work. Codes were added as they emerged from the data until saturation was achieved, and initial transcript sections were recategorized using the reformulated codes. Each transcript was coded by two researchers, who achieved at least a 90% agreement rate in independent coding. Dedoose allows for the assembling of coded segments into selected configurations that facilitates identification of recurring patterns/clusters.
Mean and standard deviation were calculated for continuous variables and percentages for categorical variables. Mean BACE scores were calculated for three subscales (stigma, instrumental barrier, and attitudinal barrier) and total score. Reliability of the BACE was measured using Cronbach's alpha for the BACE total scale (0.91), BACE stigma subscale (0.91), BACE instrumental barriers scale (0.77), and BACE attitudinal barriers scale (0.82). Reliability for the EPDS was 0.86.
Results
The population studied represented a diverse sample (Table 1) . Based on the M.I.N.I., all participants met diagnostic criteria for bipolar illness and most had comorbid illnesses ( Table 2 ). The total BACE score and stigma, instrumental barriers and attitudinal barriers, and access to care subscales were low. While the majority had received a mental health diagnosis (n = 21, 84.0%) or psychiatric treatment (n = 21, 84.0%) in their lifetime, only seven (28.0%) were referred for treatment during pregnancy and only six (20.83%) had a clinical diagnosis of bipolar disorder documented in their medical record (Table 3) . Of those who were prescribed medication (n = 14, 58.33%), most were treated with an antidepressant alone (n = 10, 71.42%), a management approach that is not consistent with current treatment guidelines for bipolar disorder (Bipolar disorders in adults: NICE Guideline 2015).
Qualitative data
Participant interviews revealed themes that reflect barriers and facilitators to their obstetric providers addressing mental health during perinatal period. While all participants had a diagnosis of bipolar disorder based on the M.I.N.I., most were unaware of their diagnosis and thus focused on concerns about depression rather than bipolar disorder.
Patient-level barriers
Self-blame, stigma, fear, and lack of support prevent women from seeking help Participants felt embarrassed that they were experiencing psychiatric symptoms due to a perception that women should not need emotional support during pregnancy or the postpartum period. They reported being scared to reach out for help due to fear of being judged.
BI don't think that it was that no one was there… it was more of me being scared of reaching out to people and letting them know that I don't have the perfect family. I think it was that fear.L ack of support from their spouse or partner contributed to these fears and made it even more challenging to seek help. Several women reported that their partner discouraged them from seeking help, because their partner said they, Bdon't need it… and just need to calm down and stop crying.L imited time and resources, competing demands, child care responsibilities, and being pregnant made it even harder for women to prioritize and take care of themselves and their mental health, so they, Bput it on the backburner… because there is no time for me.^Women also blamed themselves and Mood disorders and the risks and benefits of treatment are not discussed or addressed by obstetric providers Participants perceived lack of discussion of options as a major omission in their prenatal care.
BThey didn't offer much advice or anything about the medication… they just kind of said what medication are you on and put it in the computer, and didn't really talk to me about it or anything. I would like to hear his opinion, how he feels about the medication… and the depression and all those kinds of things… I didn't really get that.Ŝ everal participants noted that their provider did not ask questions about or provide information about their mood disorder or the risks and benefits of the psychiatric medications they were taking during pregnancy or breastfeeding. One participant stated, BI do wanna breastfeed, but I get scared because I don't know… what that [medication] is going to do my child and I don't want my child to have issues any issues with the medication going through my breast.'L ack of follow-through of screening results among providers Participants felt discouraged when their provider did not pay attention to the answers to the depression screen or did not discuss the results. One participant shared her experience:
BThey do the survey… but they don't discuss [it]… they just give you the survey, BHere fill this out.^There's no discussion about it…M ultiple participants felt they filled out the screen and Bthat was it.^They also noted that other important topics related to their emotional health and overall well-being were not discussed such as Bthe obvious, are you nauseous, gain weight, lose weight, whatever... it is never really [discussed].Ŝ ystem-level barriers Unable to find providers who treat pregnant women with mood disorders Participants noted that depression screening had limited utility, because they did not know where to go for help. One participant noted:
BI saw that some other women in the group had problems with like waiting times to get into groups or services, which seemed unreasonable. Especially during postpartum when time is very important.B arriers to accessing mental health care included the participants' limited knowledge regarding available providers, in addition to encountering unresponsive providers, and long wait times for appointments.
Patient-level facilitators
Feeling empowered by knowledge about illness and importance of treatment Women felt empowered when they had information and knowledge about mental health complications during pregnancy and available treatments. They noted that it helped when friends, family members, or partners checked in on them periodically and asked about their mental health or suggested they reach out for help.
BThe knowledge of mental health. I think it is probably the biggest thing, knowing, recognizing the signs and symptoms. Just knowing that I needed to seek help before it got worse.Ô penness to discussing their mental health concerns among themselves and other women was greatly valued by many participants and was noted to help them feel better that they Bfeel the same that I am [feeling] .P
rovider-level facilitators
Obstetric providers detecting and discussing mood disorders and referring women for treatment Participants suggested obstetric providers encourage women to disclose their concerns about their mental health and let them know where they can go to seek help. Women wanted their obstetric provider to refer them for treatment and be the gateway for more specialized treatment when needed.
BIt is more not [being] omen also wanted their obstetric provider to be more insistent about them getting treatment. Participants suggested that obstetric providers discuss mental health disorders that that can occur before, during, and after birth with women and their partners or family. They noted this would help them seek help and act on any concerns that may arise.
System-level facilitators
Increasing awareness of mood disorders through education and provision of resources Participants wanted to be informed about the available treatment for mood disorders and how to seek help should they occur. Several noted that Bdoctors should have something [to give them] and should talk about it at every visit,^even when there is no psychiatric history. Participants noted how helpful it would be if obstetric providers routinely discussed mental health resources and treatment options and start this early in pregnancy to help women and their supports recognize mood disorder symptoms and seek help.
BEvery time they go to doctor visits, the Ob/Gyn needs to talk about it, at every visit. Even if the woman looks happy, there's always something. I think if the doctors would mention it all the time, every pregnancy, it would get through their head that maybe it's a serious thing.Ŝ creening coupled with coordination and consistent followup of care To engage and support women getting treatment, participants suggested that screening should be coupled with a follow-up discussion, education, coordination of treatment, and periodic check-ins and/or follow-up phone calls to ensure that women got connected with treatment.
B…especially when I was having trouble and there was a lot of pressure on my husband. I feel like that shouldn't be only for people who can afford it, I think that should be somehow accessible to everybody with a psychiatric problem.D
iscussion and conclusion
While all women in our sample met the criteria for bipolar disorder based on the MINI, they (1) were not clinically diagnosed with bipolar disorder and (2) did not receive targeted treatment for bipolar disorder. Despite having met the criteria for bipolar disorder on the M.I.N.I., most women had not been given a clinical diagnosis of bipolar disorder (72.0%). This is consistent with prior work in general adult populations in which misdiagnosis of bipolar disorder is common (Hirschfeld et al. 2003; Hirschfeld and Vornik 2004) , with typically a 10-year lag between onset of illness and receipt of correct diagnosis (Ghaemi et al. 2000a, b) . Almost half the sample (42%) received inappropriate/relatively contraindicated medication treatment (i.e., antidepressant monotherapy) (Bipolar disorders in adults: NICE Guideline 2015). Similarly, almost half (42%) received no medication treatment, which is also inconsistent with current treatment guidelines.
Given that all the women in our sample screened positive for depression and were not diagnosed with bipolar disorder, it is understandable that some received treatment with antidepressant medication. Antidepressant medication is an appropriate, evidence-based treatment for unipolar depression but not for bipolar disorder. Research suggests a lack of efficacy of antidepressant treatment for bipolar depression (Sachs et al. 2007; Sidor and MacQueen 2011) with concomitant risk of cycling/switching between episodes of depression or hypomania/mania Schneck et al. 2008) . Use of antidepressant monotherapy in bipolar disorder, type II has more supporting evidence (Amsterdam and Shults 2010; Amsterdam et al. 2010) with lower risk of switching in bipolar disorder, type II relative to type I (Altshuler et al. , 2017 . However, increased rates of suicidal ideation and attempts are associated with antidepressant exposure (Bauer et al. 2006; Pacchiarotti et al. 2011) . Currently, evidence-based guidelines recommend use of antidepressants only in conjunction with mood stabilizers (Bipolar disorders in adults: NICE Guideline 2015). Thus, in our study, most women with bipolar illness were neither correctly identified nor offered evidence-based treatment for bipolar disorder because they were either not treated or treated with antidepressants alone (68.0%). Although this was a severely ill population in which most participants had a history of psychiatric treatment with pharmacotherapy and a past suicide attempt, most also reported that they were not given the opportunity to discuss medication treatment options during pregnancy.
Despite these challenges, women reported experiencing low stigma and the majority received at least some form of mental health treatment. Most treatment was provided by nonpsychiatric providers, suggesting that obstetric practices play a critical role in providing psychiatric care to this population. This is major progress and an important step in increasing access to mental health care for perinatal mood disorders. Our qualitative data suggest that women want their obstetric providers to proactively screen for, discuss, and help them obtain mental health treatment.
Although the obstetric providers' increased comfort in treating perinatal depression is a major advance, our data suggest that it also may be associated with an increased risk of delivering inappropriate treatment to women with undiagnosed bipolar disorder, including antidepressant monotherapy. Our data are particularly concerning because our study sample was a high-risk population in which the majority had attempted suicide or had been psychiatrically hospitalized, both of which are predictors of poor course and outcomes.
Bipolar disorder is complicated illness that can be difficult to diagnose (Smith et al. 2011 ). Patients that screen positive for bipolar disorder will generally need to be assessed by a psychiatric provider for diagnostic clarification. While it may not be appropriate or feasible for obstetric providers to diagnose bipolar disorder, it is imperative that they screen for it before initiating treatment with an antidepressant. Screening with a validated screening tool would allow obstetric providers to determine when it is appropriate to initiate treatment with an antidepressant versus refer for assessment and treatment with a psychiatric provider. This approach is consistent with the Maternal Mental Health Safety Bundle (Kendig et al. 2017 ) which recommends screening for bipolar disorder in obstetric settings.
Study strengths include that we obtained both qualitative and quantitative data, allowing for more in depth understanding of the participants' experiences. Our study is limited by a small sample of women with severe psychiatric illness drawn from a single geographic region, which limits generalizability. Further investigation in larger and more diverse samples in different geographic regions is needed to increase the generalizability of our findings.
Although we purposefully sampled women with bipolar disorder, our qualitative findings may also apply to other psychiatric illnesses that occur during pregnancy and the postpartum period. For example, because there was no comparison group, it is possible that the barriers to care in our sample are similar to those experienced by women who do not meet criteria for bipolar disorder. Differentiating the barriers experienced by women with and without unrecognized bipolar disorder would also have allowed us to better understand the different barriers experienced by these subsets of women in our sample. Including data on the perspectives of obstetric providers would also have enhanced our findings. Regardless, our study builds on previous research to better understand the experiences of perinatal women with bipolar disorder.
Our data suggest that pregnant women with bipolar face many challenges in securing mental healthcare treatment appropriate to their needs. To promote maternal, and ultimately child health, bipolar disorder must be recognized, treated, and carefully monitored. Obstetric providers are at the front line serving these vulnerable women with complex conditions. As recommended in the Maternal Mental Health Safety Bundle (Kendig et al. 2017) , these settings can and should be leveraged as a place to detect bipolar disorder and refer patients for treatment. Obstetric providers play a pivotal role in this process. Our data suggests that obstetric providers need to identify women with bipolar disorder and help link women with needed psychiatric care to (1) avoid inappropriate and potentially dangerous prescribing practices for the women who have undiagnosed bipolar disorder and (2) ensure women are referred to the specialized treatment they need. 
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